| CTI Exchange

Provision of contraceptive prescriptions following medication abortion in Australian general practice: a national longitudinal study using MedicineInsight, 2013 to 2022

Clinical evaluation of a low-cost and high-fidelity animal model for palpable and nonpalpable implant removal

Contraceptive Quality Performance Measures to Advance Patient-Centered Care

User: Female
Hormonal: Non-Hormonal
Delivery Type: Vaginal Gel
Intended Duration: Pericoital
Development Stage: Phase II
Developer(s)/Researcher(s): National Research Institute for Family Planning, China

User: Female
Hormonal: Hormonal
Delivery Type: Transdermal
Intended Duration: Short-Acting
Development Stage: Phase III
Developer(s)/Researcher(s): Viatris

User: Female
Hormonal: Hormonal
Delivery Type: Oral
Intended Duration: Emergency
Development Stage: Phase III
Developer(s)/Researcher(s): The University of Hong Kong

User: Female
Hormonal: Hormonal
Delivery Type: Oral
Intended Duration: Emergency
Development Stage: Phase II
Developer(s)/Researcher(s): University of Colorado, Denver

User: Female
Hormonal: Hormonal
Delivery Type: Injectable
Intended Duration: Emergency
Development Stage: Phase I
Developer(s)/Researcher(s): University of Southern California

User: Female
Hormonal: Non-Hormonal
Delivery Type: Fallopian Tube
Intended Duration: Permanent
Development Stage: Discovery & Early Development
Developer(s)/Researcher(s): Third Xiangya Hospital of Central South University, Shanghai East Hospital of Tongji University

User: Female
Hormonal: Hormonal
Delivery Type: Vaginal Gel
Intended Duration: Not Yet Determined
Development Stage: Pre-Clinical
Developer(s)/Researcher(s): University of Lagos